MedTrace Logo

Vortioxetine to Prevent Return of Symptoms in Children With Depression

NCT05014919 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-01-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.

Conditions

Interventions

DRUG

Vortioxetine

Tablets

DRUG

Placebo

Tablets

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-10
Primary Completion
2022-03-31
Completion
2022-04-28
FDA Drug
Yes

Countries

  • United States
  • Colombia
  • Latvia
  • Mexico
  • Poland
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05014919 on ClinicalTrials.gov